Proteasome inhibition and Parkinson's disease modeling
- 21 July 2006
- journal article
- editorial
- Published by Wiley in Annals of Neurology
- Vol. 60 (2), 260-264
- https://doi.org/10.1002/ana.20937
Abstract
No abstract availableThis publication has 19 references indexed in Scilit:
- A human single-chain Fv intrabody blocks aberrant cellular effects of overexpressed α-synucleinMolecular Therapy, 2004
- Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's diseaseAnnals of Neurology, 2004
- D-β-Hydroxybutyrate rescues mitochondrial respiration and mitigates features of Parkinson diseaseJCI Insight, 2003
- Parkinson's Disease: Mechanisms and ModelsNeuron, 2003
- Impairment of the Ubiquitin-Proteasome System by Protein AggregationScience, 2001
- α‐Synuclein Up‐Regulation in Substantia Nigra Dopaminergic Neurons Following Administration of the Parkinsonian Toxin MPTPJournal of Neurochemistry, 2000
- Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson diseaseNature Medicine, 1999
- Bcl-2: Prolonging Life in a Transgenic Mouse Model of Familial Amyotrophic Lateral SclerosisScience, 1997
- Dose-dependent lesions of the dopaminergic nigrostriatal pathway induced by instrastriatal injection of 6-hydroxydopamineNeuroscience, 1995
- Differences in Nigral Neuron Number and Sensitivity to 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57/bl and CD-1 MiceExperimental Neurology, 1994